We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+60.07%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
+$508M
Cap. Flow
+$101M
Cap. Flow %
6.94%
Top 10 Hldgs %
68.34%
Holding
42
New
5
Increased
14
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$37.1M
2
SYRE icon
Spyre Therapeutics
SYRE
+$28.6M
3
OCUL icon
Ocular Therapeutix
OCUL
+$23M
4
ATXS
Astria Therapeutics
ATXS
+$17.8M
5
ARVN icon
Arvinas
ARVN
+$14.7M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$23.5M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$18.7M
3
SVRA icon
Savara
SVRA
+$14.1M
4
GHRS icon
GH Research
GHRS
+$10.1M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$8.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$251M 17.19%
4,030,471
+13,624
+0.3% +$339K
APGE icon
2
Apogee Therapeutics
APGE
$10.1B
$237M 16.28%
8,493,321
– –
PHVS icon
3
Pharvaris
PHVS
$2.28B
$95.2M 6.53%
3,395,606
+1,832,093
+117% +$37.1M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.09B
$84.6M 5.8%
3,882,623
+800,001
+26% +$12.6M
FDMT icon
5
4D Molecular Therapeutics
FDMT
$532M
$69.4M 4.76%
3,424,031
+424,031
+14% +$5.58M
MRUS
6
DELISTED
Merus
MRUS
$59.1M 4.05%
2,148,214
+422,000
+24% +$9.85M
CABA icon
7
Cabaletta Bio
CABA
$437M
$58.2M 3.99%
2,563,952
+590,699
+30% +$9.93M
SYRE icon
8
Spyre Therapeutics
SYRE
$8.54B
$51.1M 3.5%
2,372,714
+2,077,680
+704% +$28.6M
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$50.1M 3.44%
4,092,731
+1,176,064
+40% +$10.7M
ELVN icon
10
Enliven Therapeutics
ELVN
$3.92B
$40.9M 2.8%
2,954,902
– –
OCUL icon
11
Ocular Therapeutix
OCUL
$1.79B
$34.7M 2.38%
+7,775,760
New +$23M
HLVX
12
DELISTED
HilleVax
HLVX
$33.3M 2.28%
2,075,000
+37,687
+2% +$501K
AMAM
13
DELISTED
Ambrx Biopharma Inc
AMAM
$29.5M 2.02%
2,070,000
– –
TERN
14
DELISTED
Terns Pharmaceuticals
TERN
$29.2M 2%
4,497,117
+1,404,844
+45% +$7.43M
DYN icon
15
Dyne Therapeutics
DYN
$4.7B
$28.9M 1.98%
2,173,913
– –
COGT icon
16
Cogent Biosciences
COGT
$6.65B
$27.5M 1.89%
4,684,167
– –
CELC icon
17
Celcuity
CELC
$4.21B
$27.5M 1.88%
1,885,538
-219,848
-10% -$2.65M
MRSN
18
DELISTED
Mersana Therapeutics
MRSN
$26.3M 1.8%
453,120
– –
ARVN icon
19
Arvinas
ARVN
$518M
$25.8M 1.77%
+627,788
New +$14.7M
ATXS
20
DELISTED
Astria Therapeutics
ATXS
$24.8M 1.7%
+3,225,806
New +$17.8M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$6.81B
$22.8M 1.56%
495,983
-594,017
-54% -$18.7M
ORIC icon
22
Oric Pharmaceuticals
ORIC
$1.15B
$22.3M 1.53%
2,428,385
+285,529
+13% +$2.06M
APLT
23
DELISTED
Applied Therapeutics
APLT
$20.9M 1.44%
6,250,000
+591,966
+10% +$1.47M
TSHA icon
24
Taysha Gene Therapies
TSHA
$1.68B
$18.4M 1.26%
10,412,872
-4,031,572
-28% -$8.04M
SVRA icon
25
Savara
SVRA
$1.12B
$16.4M 1.13%
3,500,000
-3,684,865
-51% -$14.1M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2023 Portfolio in Review

As of Q4 2023, VR Adviser held 42 positions worth $1.46B, up 53% from $950M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

VR Adviser deployed $101M of net new capital in Q4 2023, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Ocular Therapeutix: 7,775,760 shares worth $34.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Rhythm Pharmaceuticals, an estimated $18.7M trimmed.

  • VR Adviser's largest Q4 2023 buy was Ocular Therapeutix: 7,775,760 shares worth $34.7M.
  • VR Adviser added most to Pharvaris in Q4 2023, an estimated $37.1M increase.
  • VR Adviser's biggest Q4 2023 reduction was Rhythm Pharmaceuticals, cutting an estimated $18.7M.
  • VR Adviser fully exited Travere Therapeutics in Q4 2023, selling an estimated $23.5M.
  • VR Adviser's ten largest holdings make up 68% of its $1.46B portfolio in Q4 2023.
  • VR Adviser opened 5 new positions and closed 6 in Q4 2023.
  • VR Adviser's portfolio value rose 53% quarter-over-quarter to $1.46B.

Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.